Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Sensyne Health appoints Non-Executive Director

18th Dec 2020 07:00

RNS Number : 0890J
Sensyne Health PLC
18 December 2020
 

 

Board Appointment

 

Tony Bourne to join as Independent Non-Executive Director

 

Oxford, U.K. 18 December 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announced the appointment of Tony Bourne to the Board as Independent Non-Executive Director with effect from 31 January 2021. He will also serve as Chair of the Remuneration Committee.

 

Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.

Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.

Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said

"I'm delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth - building an innovative world class clinical data and artificial intelligence company."

 

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

 

Full name and age: Anthony (Tony) Rhys Bourne (age 67)

 

Current Directorships or Partnerships:

 

153 Holland Park Avenue RTM Company Limited

Barchester Healthcare Limited

Barchester Holdco (Jersey) Limited

Barchester Finco 2019 Limited

Barchester Hellens Limited

CWPlus

Grove Limited

Spire Healthcare Group plc

Totally plc

 

Directorships or Partnerships within the last five years

 

Bioquell Limited

CWHC Trading Limited

Remedium Partners Limited

Universal Drilling & Cutting Equipment Limited

Universal Engineering Holdings Limited

VirtualStock Holdings Limited

VirtualStock Limited

 

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

 

 

 

-ENDS-

 

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 0581845

Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer

Michael Norris, Interim Chief Financial Officer

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418900

Dr Christopher Golden

James Steel

Oliver Jackson

Liberum (Joint Broker)

+ 44 (0) 201002000

Bidhi Bhoma

Euan Brown

Consilium Strategic Communications

+44 (0) 7780600290

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

[email protected]

 

About Sensyne Health

 

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFDLLFBLLFFBF

Related Shares:

SENS.L
FTSE 100 Latest
Value8,809.74
Change53.53